Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1605 • 2016 ACR/ARHP Annual Meeting
Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Roy Fleischmann¹, Mark C. Genovese², Janet van Adelsberg³, Erin Mangan⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶ and TWJ Huizinga⁷, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab (150 or 200 mg every 2 weeks [q2w] subcutaneously) + MTX demonstrated efficacy vs placebo…
Abstract Number: 1632 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
Mark C. Genovese¹, Roy Fleischmann², Erin Mangan³, Janet van Adelsberg⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶, Chunpeng Fan⁷ and Tom WJ Huizinga⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Biostatistics, Sanofi Genzyme, Bridgewater, NJ, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy of sarilumab + MTX was demonstrated in patients with RA and inadequate response to MTX…
Abstract Number: 1633 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis
Désirée van der Heijde¹, Janet van Adelsberg², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez⁴, Erin Mangan⁵, Neil Graham⁵, Deborah Dukovic³, Alberto Spindler⁶ and Mark C. Genovese⁷, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Sanofi Genzyme, Cambridge, MA, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Universidad Nacional Tucumán, Yerba Buena Tucuman, Argentina, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab + MTX demonstrated significant improvements in RA signs and symptoms, physical function, and inhibition of…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 2054 • 2016 ACR/ARHP Annual Meeting
Effect of Temporary Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Jin Kyun Park¹, Min Ah Lee Lee², Kyung Hee Lee², Eun Young Lee¹, Yeong Wook Song³, Yunhee Choi⁴, Kevin L. Winthrop⁵ and Eun Bong Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ²Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, The Republic of, ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea, ⁴Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea, The Republic of, ⁵Oregon Health and Sciences University, Portland, OR, ⁶Seoul National University, Seoul, Korea, Republic of
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a higher risk of infection due to the underlying immune dysfunction and immune suppression associated with treatment.…
Abstract Number: 2497 • 2016 ACR/ARHP Annual Meeting
Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis
Cecilia Lourdudoss¹, Alicja Wolk², Lena Nise³, Lars Alfredsson⁴ and Ronald F. van Vollenhoven¹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ²Unit of Nutritional Epidemiology, Dept of Environmental Medicine, Karolinska institutet, Stockholm, Sweden, ³Unit of Cardiovascular Epidemiology, Dept of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: We hypothesized that increased dietary intake of vitamin D and omega-3 fatty acids (FA) prior to disease modifying anti-rheumatic drug (DMARD) initiation may associate…
Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting
Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Soledad Retamozo¹, Maria Jezabel Haye Salinas², Juan Pablo Pirola³, Diego Baenas², Ana C. Alvarez⁴, Veronica Saurit³, Alejandro Alvarellos⁵, Christian A. Waimann⁶, Gustavo Citera^7,8, Fernando Dal Pra⁹, Celeste Orozco⁹, Federico Ceccato¹⁰, Sergio Paira¹⁰, MV Martire¹¹, G Crespo Amaya¹¹, Anastasia Secco¹¹, M Mamani¹¹, Javier Rosa¹², Enrique Soriano¹², Josefina Marcos¹³, Mercedes Argentina García¹⁴, Carolina Costi¹⁵, María M Zalazar¹⁶, Alejandro Martinez Muñoz¹⁶, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Javier Velozo¹⁹, Vicente Ricardo Juarez²⁰, M Crespo²⁰, A Quinteros²¹, M Leal²¹, G Salvatierra²², Monica Sacnún²³, R Quintana²³, M Abdala²⁴ and Francisco Caeiro²⁵, ¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina, ⁵Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁶Escuela Superior de Ciencias de la Salud, UNICEN., Olavarria,, Argentina, ⁷Rheumatology, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, ⁸Rheumatology, CONAART - IREP, Buenos Aires, Argentina, ⁹Instituto De Rehabilitación Psicofísica, Argentina, CABA, Argentina, ¹⁰Hospital Dr José María Cullen, Santa Fe, Argentina, ¹¹Hospital Bernardino Rivadavia, CABA, Argentina, ¹²Hospital Italiano De Buenos Aires, CABA, Argentina, ¹³Hospital San Martin, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁵Hospital San Martín, LaPlata, Argentina, ¹⁶Hospital Pirovano, CABA, Argentina, ¹⁷Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁸Centro Médico Privado De Reumatología (Tucumán), Tucumán, Argentina, ¹⁹Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁰Hospital Señor Del Milagro, Salta, Argentina, ²¹Centro Integral De Reumatología, Tucumán, Argentina, ²²Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²³Hospital Provincial De Rosario, Rosario, Argentina, ²⁴Hospital Provincial Del Centenario, Rosario, Argentina, ²⁵Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina
Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…
Abstract Number: 2522 • 2016 ACR/ARHP Annual Meeting
Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response
Carles Ubeda¹, Shahla Abdollahi-Roodsaz², Steven B. Abramson³ and Jose U. Scher⁴, ¹Institute for Research in Public Health, Valencia, Spain, ²Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in the therapeutics of inflammatory arthritides, methotrexate (MTX) remains the mainstay of treatment for rheumatoid arthritis (RA) and related conditions worldwide.…
Abstract Number: 23 • 2016 ACR/ARHP Annual Meeting
Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: The prevalence and characteristics of patients with nonalcoholic fatty liver disease (NAFLD) have not been well characterized in the RA population. The purpose of…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
Abstract Number: 565 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Gastrointestinal Tolerance in Patients with Rheumatoid Arthritis and Methotrexate Daily Doses
Adriana Nallely Rangel-Botello¹, Marco Ulises Martinez-Martinez², Carlos Abud Mendoza¹, Alexa Bazua Gerez³, Ángel Cárdenas Hernández³, Luis Domínguez Salgado³, José Espinoza Martínez³, Héctor García González³, Oswaldo González Rivera³, Gustavo Hernández de la Cruz³, Germán Magaña Ávila³, Miguel Martínez Rojas³ and Mariana Moctezuma Dávila³, ¹Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ²Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ³Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. We reported the liver safety with daily dose of MTX1. Weekly doses of MTX…
Abstract Number: 2561 • 2016 ACR/ARHP Annual Meeting
A Novel Pharmacological Action of MTX on RA Fibroblast-like Synoviocytes Via Circadian Clock Genes
Kohjin Suzuki¹, Kohsuke Yoshida¹, Teppei Hashimoto², Kenta Kaneshiro¹, Ayako Nakai¹, Naonori Hashimoto¹, Yoshiko Kawasaki², Nao Shibanuma³, Natsuko Nakagawa⁴, Yoshitada Sakai⁵ and Akira Hashiramoto⁶, ¹Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, ³Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁴Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, ⁵Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: The circadian rhythm is disrupted in patients with rheumatoid arthritis (RA), and we have shown that tumor necrosis factor(TNF)-ƒ¿ inhibits the expression of circadian…
Abstract Number: 645 • 2016 ACR/ARHP Annual Meeting
Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
René-Marc Flipo¹, Cécile Gaujoux-Viala², Christophe Hudry^3,4, Elena Zinovieva⁵, Eric Leutenegger⁶ and Hélène Herman-Demars⁵, ¹Rheumatology Department, Lille University Hospital Roger Salengro, Lille, France, ²Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology Institute, 75008, France, ⁵Medical Department Nordic Pharma, Paris, France, ⁶GECEM, Montrouge, France
Background/Purpose: Current guidelines consider MTX as initial gold standard treatment for patients (pts) with RA. They also propose various strategies for MTX inadequate responders, among…
Abstract Number: 2637 • 2016 ACR/ARHP Annual Meeting
Clinical Trials Aiming to Prevent the Development of Rheumatoid Arthritis Cannot Detect Prevention without Adequate Risk Stratification; A Trial Performed in UA-Patients As Example
Leonie E Burgers, Cornelia F Allaart, Tom WJ Huizinga and Annette HM van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Prevention of rheumatoid arthritis (RA) was the aim of several clinical trials performed in undifferentiated arthritis (UA). Overall these trials had negative results. As…
Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Daniel Erhardt¹, Brian C Sauer², Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴ and Grant W. Cannon², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…

« Previous Page
1
…
5
6
7
8
9
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].